# Xeris Pharmaceuticals (XERS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/XERS
## Company Profile
- Ticker: XERS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 8.49 USD
- Market cap: 1035852330 USD
- Last updated: 2026-08-12
## Business Overview
### Specialty Biopharmaceutical Portfolio
Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
### Endocrine Products
Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome. Gvoke is a ready-to-use liquid glucagon for severe hypoglycemia. Keveyis is an oral therapy for primary periodic paralysis. Together, the portfolio gives Xeris a multi-product commercial platform serving specialist prescribers and patients with chronic or episodic endocrine disorders.
## Why The Stock Is Moving

As of Aug 12, 2026, XERS closed up 1.19% at $8.49. No new same-company headline was identified in the current news window.

## Recent News
- 2026-08-06 11:00 EST — [Xeris Biopharma Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/XERS/xeris-biopharma-reports-second-quarter-2026-financial-results-d07d833f) — Source: Xeris Pharmaceuticals
- 2026-07-23 11:30 EST — [Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/XERS/xeris-biopharma-to-report-second-quarter-2026-financial-results-on-august-6-2026-2634780e) — Source: Xeris Pharmaceuticals
- 2026-07-02 20:05 EST — [Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)](https://biopharmsignal.com/news/XERS/xeris-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-713b1411) — Source: Xeris Pharmaceuticals
- 2026-07-02 20:05 EST — [CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)](https://biopharmsignal.com/news/XERS/correcting-and-replacing-xeris-announces-inducement-grants-under-nasdaq-listing--0c3e5deb) — Source: Xeris Pharmaceuticals
- 2026-06-30 11:00 EST — [Xeris Announces Updates to Its Board of Directors](https://biopharmsignal.com/news/XERS/xeris-announces-updates-to-its-board-of-directors-f32772e5) — Source: Xeris Pharmaceuticals